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ABSTRACT
A Physiologically-Based Pharmacokinetic Model for Vancomycin
by
Rebekah White
Vancomycin is an antibiotic used for the treatment of systemic infections. It is given
intravenously usually every twelve or twenty-four hours. This particular drug has a
medium level of boundedness, with approximately fifty percent of the drug being free
and thus physiologically effective. A physiologically-based pharmacokinetic (PBPK)
model was used to better understand the absorption, distribution, and elimination of
the drug. Using optimal parameters, the model could be used in the future to test
how various factors, such as BMI or excretion levels, might affect the concentration
of the antibiotic.
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1 INTRODUCTION
The inspiration for this research into the PBPK modeling of vancomycin was
based on the work and thesis of a former ETSU graduate student Whitney Forbes
[6]. Her research involved the development of this type of model to study ertapenem
and the effects BMI has on this drug’s physiological properties. The original goal of
this research was to determine if BMI affected the concentration of vancomycin in
the same manner. This thesis uses a similar methodology to develop a model for the
concentration of vancomycin in the body, which can later be tested across various
BMI levels.
Vancomycin, depicted in Figure 1, “is an amphoteric glycopeptide antimi-
crobial substance produced by the growth of certain strains of Nocardia orientalis”
[12, 22]. It is a broad spectrum antibiotic and the first line of defense for the treat-
ment of methicillin-resistant Staphylococcuss aureus (MRSA). It is commonly used
to treat infections of the bloodstream and skin as well as meningitis [3]. Vancomycin
was isolated from soil samples collected in the jungles of Borneo by a missionary, Ed-
mund Kornfeld, in 1953. It was soon realized that bacteria did not build up resistance
to the drug as quickly as to other antibiotics such as penicillin. For this reason its
name was derived from the word “vanquish” [11]. It is a moderately bound antibiotic
with the protein binding of vancomycin being approximately 55%. It is primarily
eliminated via the renal route, with 80%–90% recovered unchanged in urine within
24 hours after administration of a single dose. The remaining drug is eliminated in
the stool. There is no apparent metabolism of the drug [19]. The average dose for
an adult with healthy renal function is 1 gram every 12 or 24 hours. The infusion
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Figure 1: Vancomycin
time is 1 hour. Some important partition coefficients include its solubility in water,
Sw = 0.255 as well as its solubility in n-octanol:water, Kow = 0.000794328, [1]. The
use of these will be clear as the model is developed.
Physiologically-based pharmacokinetic (PBPK) modeling examines how drugs
are utilized by the human body by examining the factors that affect absorption, dis-
tribution, metabolism, and excretion of the drugs [3]. In building a PBPK model,
one makes decisions about which compartments will be used to model the dispersion
of the drug. Once this is decided, information regarding compartment volumes, flow
rates, and properties of the drug being studied allow the model to be developed. In
section 2 the development of this model for vancomycin is given. In sections 3, 4,
and 5 we will discuss modifications made on the base model that resulted in the final
8
PBPK model for vancomycin.
2 THE MODEL
The first step in creating a PBPK model is to determine the compartments that
will be included in the model. In order to do this, the physiological affects the drug has
on different organs or tissues of the body must be known. The route of administration
as well as how the drug is excreted is also required. This, combined with what aspect
of the drug is to be studied, determines which compartments will be included in the
model. Since the effect of BMI on absorption is the ultimate goal of this modeling
effort, which means the amount of fat is relevant. Therefore, adipose tissue (F ) must
also be a compartment. The drug is primarily excreted in the urine, with a small
amount being eliminated in the feces. This means the kidney (K) and gut (G) must
comprise two compartments in the model. All other tissues (OT ) are lumped into one
compartment. Information about the other tissues is obtained by subtracting what
is calculated regarding those five compartments from what is known about the total
body. Notice this gives us five compartments, blood, fat, kidneys, gut, and other
tissues. There are also two places of excretion, in the urine and feces. The schematic
given by Figure 2 depicts this.
9
Figure 2: Model Compartments
The next step in creating the PBPK model is to examine how the drug is
broken down or activated in the body. Specifically, what concentration of the drug
in the blood has physiological affects on the body. A portion of the drug is bound to
binding proteins in the body and rendered ineffective. What is not bound is known
as the free concentration, while the inactive part is known as the bound concentra-
tion. Although the amount of boundedness of the drug can change as plasma levels
increase, if a linear relationship between the two is present, the free concentration
can be determined based on the total concentration. For example, vancomycin is
a moderately bound drug where an increase or decrease in its free concentration is
based only on the total concentration in the blood [18]. It is known that vancomycin
is approximately fifty percent bound to plasma proteins. Because only the free con-
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centration is flows throughout the body, we need a relationship connecting the two
[7]. Together, the free concentration (CBf ) and the bound concentration (CBound)
make up the total concentration of vancomycin in the blood (CBl). This relationship
is given by
CBl = CBf + CBound.
For this particular drug, we assume initially the free concentration is a linear func-
tion of the total concentration, but we will later assume that a nonlinear relationship
exists in order to better fit the model to data (see section 5) [18]. Because of the
boundedness of vancomycin, we are able to write the free concentration as a portion
of the total concentration [2]. This is represented as
CBf = 0.51 ∗ CBl. (1)
The rate of infusion, Ri, represents the quantity of drug entering the body intra-
venously with respect to time. This is given by
RI =
{
D
TI
, 0 ≤ t ≤ TI
0, t > TI
(2)
Here, D = 1gm is the dosage and TI = 1hr is the infusion time.
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2.1 Parameters
The next part of developing the model involves determining the equations for
volumes and flow rates. These provide information regarding how the drug is dis-
tributed throughout the different compartments. It is necessary to know the volumes
of each compartment in order to examine drug dynamics for the entire system. Both
the equations for the volumes of each compartment as well as blood flow rates are
determined from literature and based on body weight (72kg) and height (1.75m) for
the average male. This portion of the model takes into account body mass and will
therefore allow us to examine how changes in body mass index will affect certain drug
factors. These are given in Equation (3). The equations for VBl and VK were from
[17], while the equation for VF was from [9] and VG from [13].
VBl =
13.1(BH ∗ 100) + 18.05(BW )− 480
0.5723
VK = 15.4 + 2.04(BW ) + 51.8(BH)
2
VF = 1.36 ∗
(
BW
BH − 42
)
∗ 1000
VG = 0.0171 ∗ (BW ) ∗ 1000, (3)
In order to account for the remaining volume of the other tissues, VOT , we will
subtract from the total body volume, the volumes above. This is given by
VOT = BW ∗ 1000− (VBl + VF + VK + VG). (4)
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From here, the amount of blood flow, and consequently drug flow, through these
compartments can be determined [21]. An equation for total flow rate in the body,
QTotal, is based upon weight [5]. The flow rates for the individual compartments can
be modeled as a fraction of QTotal. These percentages are found in literature and are
given in Table 1.
Table 1: Parameter Values Obtained from Literature
Parameter Value Units Reference
QTotal 235 ∗ (BW )0.71 ∗ 60 mL/hr [5]
QF 0.052 ∗QTotal mL/hr [13]
QK 0.19 ∗QTotal mL/hr [13]
QG 0.17 ∗QTotal mL/hr [13]
2.2 Partition Coefficients
Another important aspect of drug dispersion that must be accounted for is how
much of the drug makes it out the tissues. It may be that not all of the drug concen-
tration that enters a tissue via the blood will leave that tissue and be recirculated.
Specifically, we must know the tissue’s solubility in order to determine what concen-
tration of the drug flowing into the tissue will be trapped there. In order to take
this into account, partition coefficients are created. To calculate these partition coef-
ficients, two things from literature must be known, the solubility of the drug in water
(Sw) and the solubility of the drug in n-octanol (S0), which were given in section
1. From here, an algorithm can be used to calculate these partition coefficients, Pi,
for tissue i. Blood enters and leaves a compartment in such a way as to maintain
equilibrium. Thus, we defined an equilibrium partition coefficient for a tissue, i, as
13
Ci
Pi
. (5)
In Equation (5), Ci is the concentration in tissue i, and Pi is the partition coef-
ficient for that tissue. Notice that the concentration of drug in the blood must be
divided by a quantity in such a way as to decrease that concentration. Thus, the
concentration of drug flowing into a tissue will be greater than or equal to that which
is able to escape. These partition coefficients can be determined using an algorithm
developed by Poulin and Krishnan [15, 16]. This is given by
Pt =
([So ∗Nt] + [(Sw ∗ 0.7Pt) + (So ∗ 0.3Pt)] + [Sw ∗Wt]
([So ∗Nb] + [(Sw ∗ 0.7Pb) + (So ∗ 0.3Pb)] + [Sw ∗Wb] , (6)
where t corresponds to the specific tissue, b to the blood, and Sw, and Kow are
drug specific parameters [21]. The following equation uses Sw and Kow to calculate
the solubility in n-octanol, So.
So = Kow ∗ Sw
.
From this we could determine that So = 0.000178724. The partition coefficients
calculated from Equation (6) for each tissue in the model is given in Table 2. These
values will be considered further in section 3.
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Table 2: Partition Coefficients
Parameter Value
PF 0.0009
PK 0.9767
PG 0.8899
POT 0.9449
The last portion of creating the model involves relating all of the information
about the flow rates, volumes, and partition coefficients of all the tissues that make up
the compartments. Next, the model is condensed to systems of differential equations.
This is possible as the drug acts essentially as a rate of flow with respect to time,
entering and leaving each compartment. For example, consider Figure 3.
Figure 3: Fat to Blood Differential
This depicts the flow between the fat and blood compartments. This can be
modeled as a first order differential equation [20], which is explicitly given as
VF
dCF
dt
= QF
(
CBf − CF
PF
)
.
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The QF represents the flow rate through the fat compartment. The CBf represents
the concentration of drug flowing into the compartment, while the Ci
Pi
represents the
portion of this same concentration flowing out. Notice that the flow rate times the
difference in the entering and exiting concentrations is equal to the rate of change of
the drug concentration times the volume of the compartment.
The kidneys and gut work similarly except that the quantity excreted from the
body system must be taken into account here by subtracting the rate of excretion
times the concentration being excreted. The model assumes a linear rate of excretion.
For instance the rate of urinary excretion, dAu
dt
, could be represented by the equation
below.
dAU
dt
= kUCK
Notice this rate is equal to the constant parameter, kU , times the concentration
excreted from the kidneys. The blood compartment takes into account the initial
infusion quantity along with the recirculation quantities that are emitted from the
other compartments. For instance the portion of drug that escaped the adipose tis-
sue will re-enter the blood and thus circulate through the compartments again. The
quantities of excretion are also calculated in order to compare with literature data.
The initial conditions are zero as it is assumed there is no initial concentration of van-
comycin in the blood. The model consists of these systems of first-order differentials
being solved simultaneously at different time steps to provide drug concentrations for
the antibiotic in the body, given the assuptions in the modeling process. This can
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then be compared to literature data and the error in the model can be examined [4].
The system of equations that describe this specific system are given by Equation (7).
VF
dCF
dt
= QF
(
CBf − CF
PF
)
VK
dCK
dt
= QK
(
CBf − CK
PK
)
− kUCK
VG
dCG
dt
= QG
(
CBf − CG
PG
)
− kFCG
VOT
dCOT
dt
= QOT
(
CBf − COT
POT
)
(7)
VBl
dCBl
dt
= QF
CF
PF
+QK
CK
PK
+QG
CG
PG
+QOT
COT
POT
−QTotalCBf +RI
dAU
dt
= kUCK
dAF
dt
= kFCG,
Notice in the equations given above, the only parameter values not gathered from
data or explicitly calculated are kU and kF . These will be estimated in section 2.3.
Table 3 lists all the parameters and variables for this model.
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Table 3: Model Variables and Parameters
Symbol Description Units
Ci Concentration of vancomycin in tissue i mcg/mL
CBf Concentration of free vancomycin in the blood mcg/mL
AU Amount of vancomycin in the urine mcg
AF Amount of vancomycin in the feces mcg
Vi Volume of tissue i mL
Qi Flow rate in tissue i mL/hr
α Infusion Coefficient dimensionless
t Time hr
Pi Blood partition coefficient in tissue i dimensionless
BW Body Weight kg
BH Body Height m
Ri Rate of Infusion mcg/hr
D Dose mcg
Ti Length of infusion hr
kU First-order rate constant of urine excretion mL/hr
kF First-order rate constant of feces excretion mL/hr
2.3 Inverse Problem
PBPK modeling makes use of known physiological parameters such as blood flow
rates through particular tissues, body weight, and organ volumes. It also incorporates
estimated parameter values such as rate of excretion in urine (ku) and feces (kF ). In
order to determine which values for these parameters optimize the model so as to
mimic the data found in literature, a least squares inverse problem is used. This will
compare differences between our literature blood concentration values versus those
the model outputs for different values of kU and kF . This is depicted in Equation (8),
where q = [ku kf ] represents the parameters to be estimated. The value of the cost
18
function is given as
J(q) =
(
N∑
j=1
(
yˆi − CBl(t, q))
CBl(t, q)
)2
+
(
0.8− AU(24)
AU(24)
)2)
. (8)
The smaller this value is, the more closely the model output will fit the literature
data.
The clinical data was obtained by extracting data from a graph using the
grabit program in Matlab [4, 10]. This data is given in Table 4. In order to determine
which values of q provide the smallest J , a built in Matlab function, fminsearch, was
used. It uses a Nelder-Mead algorithm to estimate parameters based off an initial
guess for the parameters. J is calculated by summing the squared differences between
the model output given parameters q and the literature data. This allows us to
determine the relative error in our model. From here, the software will try parameter
values generated using the Nelder-Mead algorithm and repeat the calculations. If
the new J value is better than the previous, it will continue to guess values in that
same direction. It may also choose values in the other direction to ensure that it
has chosen estimates that minimize the cost function. Once the program reaches a
certain threshold, it outputs the optimal parameter values. These optimizing values
will then be used in the model.
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Table 4: Clinical Data for the Total Concentration of Vancomycin[4]
Time (tj) Clinical Data (CBl)
(hrs) (mcg/mL)
1 63.61
1.08 53.67
1.25 46.39
1.50 38.44
2.00 29.17
2.50 24.32
3.00 21.01
3.40 18.14
4.00 15.28
5.00 12.86
7.00 9.35
9.00 6.72
13.00 4.77
2.4 Results
After running the cost function with the initial guess of q = [10000 1000] (values
of kU and kF respectively), the fminsearch program determined that the optimal
parameter values are kU = 9, 993
mL
hr
and kF = 1, 691
mL
hr
. This gave the cost function
a value of J(q) = 1.318. This value represents the sum of squared relative errors across
all the data points and excretion levels and implies the model has approximately 130%
squared error. Figure 4 depicts the urine excretion over the dosing period. This is of
importance as this is the primary route of elimination of vancomycin from the body.
Clinical data puts urine excretion at 80% of the initial dose. The model predicted
79.6% for urine excretion. The percent error between these two is 0.495%. This tells
us that the model depiction of drug excretion is very accurate. The remaining drug in
20
the body is eliminated via the gut, as virtually no amount of the drug is metabolized.
Figure 4: Urine Excretion
Figure 5 provides a graphical depiction of the model output for blood concentra-
tion versus the clinical data over the twelve hour period following the end of infusion.
The percent relative error in point estimates for the total concentration is 47.59%.
This is certainly too high a value for relative error. Notice on the graph that the
highest peak is not in line with the data. This is the area of least fit for the model.
The only area of the data that is in line with model output is at the end of the dosing
period.
21
Figure 5: Total Concentration
3 THE MODEL WITH PARTITION COEFFICIENTS AS PARAMETERS
The fit depicted in figure in the previous results is not accurate enough to con-
clude our model is a good representation of how vancomycin acts on the human body.
It may be noted that the partition coefficients in Table 2 are all values less than one.
Referring back to Equation (5), it is determined that those values do not make biolog-
ical sense as they would imply that a higher concentration of the drug is leaving the
tissues than what entered. This is likely due to the fact that the solubility in water
and n-octanol were approximated using computer software [1]. In order to improve
the model, these partition coefficients will be estimated as parameters, rather than
calculated from a formula. In order to determine which of these partition coefficients
has the greatest effect on blood concentration, sensitivity analysis was done. In order
to do this, the partial of each Equation in (7) had to be taken with respect to each of
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the six parameter values. This allows us to determine the effect each parameter has
on the concentration in each compartment. The calculation is done by normalizing
the sensitivities using the modified L2 norm
∣∣∣∣∣
∣∣∣∣∣∂Ctissue∂qj
∣∣∣∣∣
∣∣∣∣∣
2
=
[
1
tf − t0
∫ tf
t0
(
∂Ctissue
∂qj
)2
dt
] 1
2
qj
maxCtissue
. (9)
Using Equation (3), results of these calculations are depicted below [6].
Figure 6: Sensitivity Analysis
The results showed no particular partition coefficient dominated the behavior of
blood concentration over time in the various compartments. Thus, all partition coeffi-
cients would need to be estimated as parameters. We use the same cost function given
by Equation (8). Our input parameters are given by q = [PF PK PG POT ku kf ].
As previously mentioned, the partition coefficients should not be values below one.
Thus, we bound them to be greater than or equal to one during the minimization. The
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result of this change is given in Figure 7. The ending optimal parameter estimates
for the partition coefficients are essentially equal to 1. It estimates kU = 8, 298
mL
hr
and kF = 1, 212
mL
hr
.
Figure 7: Total Concentration With Partition Coefficients as Parameters
It is clear that this does not solve the problem of the peak being too low. Fur-
thermore, as the estimates for the partition coefficients, PF , PK , PG, POT , were
approximately one, we will remove these as parameters and instead set them equal
to 1. The next section will discuss alternative changes to be made to the model in
order to better improve the fit.
4 THE MODEL WITH AN INFUSION COEFFICIENT
As noted in the previous section, our model falls short in predicting the accurate
peak of vancomycin concentration in the blood. For this reason, a new parameter α
24
is introduced into the model as was done in [6]. This parameter acts as an infusion
coefficient, slowing the rate of drug dispersion throughout the compartments during
the infusion period. The infusion coefficient, α, is given by
α =
{
αI , 0 < t ≤ TI
1, TI < t < 12
.
This makes sense biologically as the quantity of vancomycin traveling through the
various compartments may not reach its maximum until the entire dose of the drug
has been administered. In addition, the way in which the drug binds during infusion
may be different than the way it binds once the entire dose is administered. This
changed the system of Equations in (7) by replacing CBf by α ∗ Cbf where α = 1
after the infusion period and is an unknown parameter during the infusion period,
which we will estimate. Now q = [ku kf α], with an initial guess of α = 0.35. The
minimization algorithm was run again to determine the optimal parameter estimates.
The estimate for α was given as 0.313, and kU = 10, 306
mL
hr
and kF = 1, 770
mL
hr
. The
solution curve for the model is plotted with the data in Figure 8. The ending cost
function value was J = 0.866. The percent relative error in point estimates for total
concentration was 33.53%.
25
Figure 8: Total Concentration With Infusion Coefficient
Notice that although the addition of α as a parameter into the model did
allow for the correct concentration peak, during the times following the peak but
before the blood concentration levels out, the model does not fit the data well. A
non-linear excretion in the urine was implemented to try to fix this problem but the
effects were negligible. The following section discusses the next steps taken to better
the model.
5 THE MODEL WITH NONLINEAR BLOOD CONCENTRATIONS
From the results given in Figure 8 it is clear that the peak blood concentration
of the model output as well as the ending blood concentrations match the literature
data fairly well. We believe the problem is in the linearity of the model during the
middle of the timespan. One possible explanation for this is that the binding of
the drug is not entirely linear. That is, Equation (1) is a linear approximation to
26
a nonlinear relationship between the free and bound concentrations of the drug in
the blood. To test this hypothesis, a nonlinear Michaelis-Menten equation is used to
model the bound concentration. This equation is given by
CBound =
BmCBf
Kd + CBf
. (10)
Here, Bm represents the blood receptor content and Kd the dissociation constant
[14]. Because the total blood concentration is the sum of the free and bound concen-
trations, using Equation (10) given above we have that
CBl = CBf +
BmCBf
Kd + CBf
. (11)
As seen in Equation (11), it is not necessary to directly calculate the bound
concentration of the drug in order to study the total and free concentrations in the
blood. Algebraic manipulation results in the following equation, which provides the
free concentration as a function of CBl, Bm, and Kd
CBf =
CBl −Bm −Kd +
√
(Bm +Kd − CBl)2 + 4KdCBl
2
. (12)
Notice there are now two additional parameters Bm and Kd. Using Equation (12)
for the free concentration in the model (Eq. (2)) along with the modified version with
the parameter α, we estimate the parameters. We use q = [Bm Kd ku kf α] in
the cost function (Eq. (8)). The results of doing this are given by Figure 9. It is clear
that the nonlinear blood concentration approach provides the most accurate model.
To verify, the cost function value after the minimization is J = 0.343. This is the
smallest value of J so far in the model development.
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Table 5: Results
Literature Concentrations [4] Model Approximations Percent Error
(mcg/mL) (mcg/mL) %
63.61 68.46 7.6
53.67 44.99 16.2
46.39 33.89 26.9
38.44 30.80 19.9
29.17 27.40 6.1
24.32 24.61 1.2
21.012 22.21 5.7
18.15 20.10 10.7
15.28 18.21 19.2
12.86 15.00 16.6
9.35 10.19 9.0
6.73 6.93 3.1
4.77 3.21 32.7
Exact Urine Excretion Approximate Urine Excretion Percent Error
(mcg/mL) (mcg/mL) %
0.800000 0.800078 0.0097%
These results can be visualized by Figure 9.
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Figure 9: Nonlinear Total Concentration
There are other import pieces of data resulting from the final model that
will be useful in future analysis. The model provided us with the area under the
curve (AUC), which is 184. This information is important as it relates again to renal
toxicity. Having too large an area could increase the risk of renal failure or other
harmful side effects of the drug. The ratio between AUC and minimum inhibitory
concentration (MIC) is also significant in trying to determine the most effective dos-
ing. Specifically, it has been related to vancomycin’s effectiveness in treating staph
infections [8]. The lowest concentration level given by the model does not fit the
lowest blood concentration as seen in Table 5. This value is of importance as the next
dose would begin at the end of the first dosing period in such a way as to ensure that
this level does not fall below the MIC in order to prevent resistance development.
This is also the area of focus when adjusting body mass. Specifically, one may be
interested in whether or not differing BMIs will cause blood concentration levels to
29
drop below the MIC.
6 CONCLUSIONS
The development of a model that provides comparable information to measure
the absorption, distribution, and elimination of vancomycin provides a solid base for
continued research regarding this drug. Specifically, it will allow for examination into
the physiological effects body mass has on these drug factors. Because compartment
volume is based of body mass, we are able to adjust these volumes according to
changes in body mass and produce model predictions based on differing body masses.
We may also be interested in differences between male and female absorption. These
could also be related to compartment volume as the average body mass for males and
females differ from one another. Another aspect of future work will be in improving
the accuracy of the model even further. One way is in evaluating the reliability of
the parameters estimated. Some of the parameters gathered from literature did not
provide useful information when input into the model. For instance, the solubility in
water and n-octanol:water of vancomycin was gathered from literature but did not
provide for biologically possible partition coefficients. For vancomycin, the lack of
data regarding its chemical properties as well data on the blood concentrations after
infusion posed some problems in developing an accurate model. Throughout the de-
velopment of the model until its final version, the parameters being estimated changed
as the model was modified. In the future, statistical analysis could be implemented to
determine confidence intervals for the parameters being estimated. This would pro-
vide information about the degree to which the model could vary based on changing
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parameters values. Overall, modifying a PBPK model for ertapenem resulted in a
reliable model of the absorption, distribution, and elimination of vacomycin [6]. The
model produced results for blood concentrations with less than a total of 15.96% error
in point estimates and less than 0.0097% error in urine excretion levels.
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